This article needs to be updated.(November 2018) |
Names | |
---|---|
Preferred IUPAC name
(4S,4aS,5aR,12aS)-4-(Dimethylamino)-7-fluoro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[2-(pyrrolidin-1-yl)acetamido]-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide | |
Other names
Xerava
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C27H31FN4O8 | |
Molar mass | 558.555 |
Pharmacology | |
J01AA13 (WHO) | |
Legal status |
|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Eravacycline (TP-434, Xerava) is a synthetic halogenated tetracycline class antibiotic by Tetraphase Pharmaceuticals. It is closely related to tigecycline. It has a broad spectrum of activity including many multi-drug resistant strains of bacteria. Phase III studies in complicated intra-abdominal infections (cIAI)[2] and complicated urinary tract infections (cUTI)[3] were recently completed with mixed results. Eravacycline was granted fast track designation by the FDA[4] and is currently available in USA.